Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1
Opus Genetics has finished dosing the second cohort in its BIRD-1 Phase 1/2 clinical trial evaluating OPGx-BEST1 for the treatment of inherited retinal diseases.
Stocks · News reference
Opus Genetics to Participate in Guggenheim Annual Healthcare Innovation Conference
Opus Genetics, Inc. announced that management will participate in a fireside chat at the upcoming Guggenheim Annual Healthcare Innovation Conference on November 10, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
Opus Genetics announced completion of dosing in Cohort 2 of its BIRD-1 Phase 1/2 clinical trial for OPGx-BEST1, a gene therapy for BEST1-related retinal diseases. The higher-dose cohort enrolled 11 participants (exceeding the target of 5) at 4.5 × 10⁹ vg/eye. Topline three-month data is expected in Q1 2027, with potential Phase 3 pivotal trial dosing anticipated in H2 2027. Cohort 1 showed favorable safety and clinically meaningful improvements in visual function across all five participants.
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Opus Genetics, Inc. announced that its Compensation Committee approved equity awards for ten new non-executive employees as a material inducement to employment.
Opus Genetics Appoints New Chief Scientific Officer and Executive Director of Executive Operations
Opus Genetics has announced the appointment of Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director of Executive Operations.
8-K filing — Opus Genetics, Inc. (IRD)
Filed: 2026-10-21 AccNo: 0001140361-26-040377 Size: 153 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Opus Genetics Wins FDA Clearance for Childhood Blindness Gene Therapy
Opus Genetics has received FDA clearance for a gene therapy treatment targeting childhood blindness.